Brendan O’Grady is the current President and CEO of Teva Pharmaceuticals’ North America Generics business and has nearly 25 years of experience in the pharmaceutical industry. As President and CEO, he is responsible for the profitability, productivity and growth for Teva’s generics business and all of its business operations in the North America region. Prior to this appointment, Mr. O’Grady held the position of Vice President and Head, US Market Access for Teva’s US Specialty business. In that capacity, he was responsible for access within all third party payer segments to include commercial, Medicaid, Medicare, federal, specialty pharmacy, as well as public and private exchanges and proactively worked with payers in the development of innovative access strategies for Teva’s branded medicines.
Teva’s Patient Services and Solutions group also reported under the U.S. Market Access umbrella and Brendan’s leadership. This team included Teva’s internal specialty pharmacy, patient support programs, customer service, call center nurses, and field based Clinical Nurse Educators. He is seen as an industry thought leader in market access issues and serves as a key internal advisor on commercial and access strategies for various global teams.
Prior to joing Teva, Mr. O’Grady spent 10 years with Sanofi predecessor companies in a variety of commercial and medical affairs roles that began in field sales. He received his B.S. from Geneseo State University (SUNY Geneseo in Geneseo, NY) in Management Science/Marketing and holds an M.B.A. from Baker University in Baldwinsville, Kansas. He currently resides in Overland Park, KS with his wife and three adult children and also maintains a residence in the Philadelphia area where he is based.